• SURFE²R N1

    簡便なオールインワン装置, アカデミックの教育ツールに最適
  • SURFE²R N1

    ラベルフリーでトランスポーターのファンクショナルHTSアッセイ系を遂に実現
  • SURFE²R N1

    パッチクランプ法を超えるシグナル増幅率
  • SURFE²R N1

    市場唯一のSSM-電気生理学システム
  • SURFE²R N1

    トランスポーター解析のターンキーシステム

2014 - Anticancer Ruthenium(III) Complex KP1019 Interferes with ATP-Dependent Ca2+ Translocation by Sarco-Endoplasmic Reticulum Ca2+-ATPase (SERCA)

Icon N1  SURFE²R N1 publication in ChemMedChem (2014)

Authors: 
Sadafi F.Z., Massai L., Bartolommei G., Moncelli M.R., Messori L., Tadini-Buoninsegni F.

 

Journal: 
ChemMedChem. (2014) 9(8):1660-4


Abstract: 

Sarco-endoplasmic reticulum Ca2+-ATPase (SERCA), a P-type ATPase that sustains Ca2+ transport and plays a major role in intracellular Ca2+ homeostasis, represents a therapeutic target for cancer therapy. Here, we investigated whether ruthenium-based anticancer drugs, namely KP1019 (indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)]), NAMI-A (imidazolium [trans-tetrachloro(1H-imidazole)(S-dimethylsulfoxide)ruthenate(III)]) and RAPTA-C ([Ru(η6-p-cymene)dichloro(1,3,5-triaza-7-phosphaadamantane)]), and cisplatin (cis-diammineplatinum(II) dichloride) might act as inhibitors of SERCA. Charge displacement by SERCA adsorbed on a solid-supported membrane was measured after ATP or Ca2+ concentration jumps. Our results show that KP1019, in contrast tocancer the other metal compounds, is able to interfere with ATP-dependent translocation of Ca2+ ions. An IC50 value of 1 μM was determined for inhibition of calcium translocation by KP1019. Conversely, it appears that KP1019 does not significantly affect Ca2+ binding to the ATPase from the cytoplasmic side. Inhibition of SERCA at pharmacologically relevant concentrations may represent a crucial aspect in the overall pharmacological and toxicological profile of KP1019.


Download here

Back

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.